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ABSTRACT 
In a previous commentary in INNOVATIONS in Pharmacy, the case was made that a major oversight in approving the establishment of 
medical marijuana programs through commercially and not-for-profit operated dispensaries is the failure to put in place standards for 
the monitoring and reporting of outcomes. It was pointed out that the evidence base is limited for the range of dosing options, 
administrative routes and conditions treated. The concern is that the ease that patients have in obtaining medical marijuana 
certification in many states means that a medical marijuana program is, in effect, little different from a recreational program. 
Dispensaries understandably focus on sales and returns to investors with scant attention given to tracking and reporting outcomes 
across the range of conditions and symptoms presented.  While this no doubt appeals to investors in reducing administration costs, it 
makes it virtually impossible to deliver the appropriate and coordinated level of care that patients should expect if a medical marijuana 
dispensary is to meet it responsibilities in its duty of care. This places dispensaries at malpractice risk. Given this, this commentary 
focuses on the questions that legislators should ask in licensing medical marijuana dispensaries to ensure they meet a defensible duty 
of care to their patients.  
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INTRODUCTION 
Do medical marijuana dispensaries have a duty of care to their 
patients? If we accept the proposition that an approved medical 
marijuana dispensary is a healthcare provider, then it is under 
a reasonable obligation to ensure that the focus is on achieving 
the best possible clinical outcomes while at the same time 
endeavoring to minimize patient harms. The notion of duty of 
care also implies that, in the delivery of care, the provider is 
obliged to attempt to ensure than the care is appropriate, that 
it is monitored and reviewed against targets set for the patient, 
and that the outcomes achieved are consistent with best 
clinical practice.  
 
The problem with botanical cannabis is that the evidence base 
for establishing the appropriate dosing regimen and 
administrative form is limited or simply non-existent for the 
range of approved conditions. The fact is that the dispensing of 
botanical cannabis for the range of disease states and 
conditions authorized under medical marijuana legislation 
occurs in what is best described as a fragmented evidence 
environment. This should give legislators pause. If there is the 
potential for harm, given the range of clinical and comorbid 
conditions presented, for example by older patients, then as 
argued in the previous commentary there needs to be a care 
management framework 1. The primary care provider or care 
manager should be linked to the dispensary and provided with 
regular real-time reports of the response to therapy.  
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Unfortunately, from the limited evidence available, this 
appears to be almost entirely absent in those states that have 
legislated for medical marijuana. There is no requirement for 
feedback to primary care providers or even specialist clinics in 
the case, for example, of severe and chronic pain. All too often, 
there is no necessary requirement that the PCP or specialist be 
involved in the certification process with certification provided 
by independent operators who may have only a limited 
knowledge of the patient’s medical history and no incentive to 
track how the patient responds to therapy; apart from a cursory 
annual re-certification. 
 
The purpose of this commentary is to make the case that a 
dispensary should meet minimum quality standards in 
monitoring and evaluating response to therapy. This has two 
benefits: (i) it demonstrates to patients, providers and 
legislators that the dispensary is committed to a duty of care in 
the provision of botanical marijuana and (ii) that the dispensary 
is committed to make a contribution through its observational 
platform to a better understanding of the evidence base for the 
contribution of botanical cannabis in the delivery of healthcare. 
The patient, after all, is the principal beneficiary and is entitled 
to the appropriate standard of care.   
 
EVIDENCE STANDARDS AND REQUIREMENTS 
In the previous commentary the limited and fragmentary 
nature of the evidence base for botanical cannabis was noted. 
More recent reviews reinforce this conclusion. Of particular 
interest is the December 2018 report of the European 
Monitoring Centre for Drugs and Drug Addiction on the medical 
use of cannabis and cannabinoids 2. The report points out that 
access to medicinal marijuana, with the few exceptions of 
prescription cannabinoids in epilepsy, has occurred without 
legislators or regulatory agencies requiring evidence standards 
that would apply in marketing authorization for new medicinal 
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products. More to the point is the absence of a strong evidence 
base for a range of conditions for which claims have been made, 
particularly against potentially more effective compounds. In 
the case of chronic non-cancer pain, including neuropathic 
pain, which is by far the most common condition treated, the 
evidence is considered moderate with a small but statistically 
significant effect for botanical cannabis compared to placebo. 
The ‘strongest’ evidence was for neuropathic pain with inhaled 
vaporized botanical cannabis. From a Bayesian meta-analysis of 
five randomized controlled trials (RCTs) (n = 178) the benefit 
over placebo was a 30% reduction in pain at 2 weeks 3. A 
Cochrane review of neuropathic pain, again against placebo, 
found a modest gain from 16 studies (n = 1750) with 21% as 
opposed to 17% achieving a 50% reduction in pain for 2 – 26 
weeks. A 30% reduction is pain was achieved by 39% of patients 
(cf. 33% placebo) 4. Finally, in a review by Stockings et al, of 
chronic non-cancer pain, 91 studies from 47 randomized clinical 
trials (n = 9958), the corresponding percentages for patients 
achieving a 30% reduction in pain was 29% for those with 
cannabinoids compared to 26% with placebo 5. While this last 
difference was statistically significant it points to two factors 
that need to be considered in legislating medical marijuana: (i) 
in a placebo comparison the results are mixed, with more 
favorable results for neuropathic pain, although across all non-
cancer pain patients the average gain in pain reduction is 
modest; and (ii) that the majority of patients in these trials 
reported either no gain or less than a 30% reduction in pain 
over the course of the study.  
 
There is no halfway house. Either there is a commitment to a 
robust program of RCTs and observational studies, with 
dispensaries having a potentially major contribution to make in 
the latter area, or we continue as we are at present with a 
fragmented and limited evidence base. Unfortunately, at 
present, only one state with a medical marijuana program, 
Minnesota, has reported on patient experience with botanical 
cannabis. Following the addition of intractable pain as a 
condition to the medical cannabis program in August 2016, a 
study was undertaken of enrollee experience during the first 5 
months of treatment (to December 2016). The healthcare 
practitioner assessed pain status with intractable pain defined 
as ‘pain whose cause cannot be removed and, according to 
generally accepted medical practice, the full range of pain 
management modalities appropriate for this patient has been 
used without adequate result or with intolerable side effects’. 
The study involved 268 health care practitioners registered with 
the state medical cannabis program who certified the 2,245 
patients covered in the report for intractable pain. The report 
draws on data assembled at each time cannabis was purchased 
at a dispensary together with surveys of both providers and 
patients.  
 
While it is not the intent here to describe the structure and 
findings from the Minnesota study in detail, there are a number 
of points to emphasize. In the first place, criticisms from an 
evidence grade perspective can be made of this and similar 
studies, in this respect the absence of a control group and the 
possibility of a significant placebo effect, reinforced by the form 
of cannabis consumed, on the outcomes reported by patients. 
Even so, the Minnesota model demonstrates the feasibility of 
establishing dispensary specific databases or registries to 
monitor the impact of botanical cannabis. Second, the 
Minnesota study points to the importance of data collection on 
patient characteristics and medical cannabis purchasing at each 
visit over the course of treatment with products classified by 
their delta-9 tetrahydrocannabinol (THC) to cannabidiol (CBD) 
ratio. Indeed, identifying these ratios points to a concern: the 
fact that very high THC products accounted for some 57% of 
product purchases, with only 5% of products classified as high 
or very high CBD. Third, the Minnesota survey points to the 
importance of linking patient responses to providers and, if 
possible, administering a parallel set of questions to providers 
(e.g., opioid utilization after initiation of botanical cannabis). 
Fourth, as the Minnesota study illustrates, it is imperative, from 
the perspective of establishing an evidence base, that it should 
be one that can link to claims from RCTs and observational 
instruments. This means a commitment to utilizing validated 
studies to establish patient status and change over the course 
of treatment. Otherwise we run into problems in establishing 
credible claim indices, evaluating claims and replicating these 
claims in other treating environments. The Minnesota study, for 
example, utilizes the validated 3-item PEG instrument 6. This 
captures three dimensions of pain experience: average pain last 
week, interference of pain with enjoyment of life and pain 
interference with general activity. Patients were also asked to 
respond to a two part Patient Self Evaluation (PSE) question: (i) 
a ranking on a scale of 1 to 7 for their perception of how much 
benefit they received (1 = no benefit; 7 = great deal of benefit 
and (ii) a write in response on the most important benefit (56% 
indicated pain reduction). A parallel survey was submitted to 
providers. The PSE responses from patients and health care 
practitioners on perceived benefits and perceived negative 
effects were reported in free-text format. These were matched 
to the patient’s assessment of benefit score and, according the 
study authors, these responses were a significant part of the 
study findings. Finally, respondents were asked also to report 
on symptoms associated with their pain: anxiety, appetite, 
depression, disturbed sleep, fatigue, nausea and vomiting. 
These are not captured by dispensaries. The reported symptom 
burden was high (apart from nausea and vomiting) with over 
50% at baseline reporting one or more symptoms (sleep 
disturbance 91%; depression 67%). Overall, some 30 to 35% of 
respondents indicated a symptom improvement of 30% and 
retaining that for 4 months. 
 
While the Minnesota study has provided a wealth of 
information on patient characteristics and the impact of 
botanical cannabis, it is only a single study. The claims 
presented for the impact of botanical cannabis should be 
evaluated in other jurisdictions. Even so, it would obviously be 
impossible to replicate the Minnesota model in treatment 
practice and it is unclear whether other state departments of 
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health would be prepared to underwrite such studies. The 
respondent burden, especially for providers, would be 
significant, particularly when the range of conditions other than 
severe pain is the focus of botanical cannabis therapy (e.g., 
persistent muscle spasms, severe nausea, seizures, PTSD) and 
where many patients present with multiple conditions. Even so, 
the Minnesota survey demonstrates what is possible. The 
question is whether, as part of dispensary practice it is possible 
to utilize a registry or database design to capture response to 
therapy, where that response is captured in clinical terms as 
well as in the patient’s own perception of the benefits of 
therapy, while at the same time minimizing respondent burden.  
 
The passing of the Farm Bill 2018 gives added weight to the 
need for evidence to support the production and adoption  of 
hemp-based CBD products. While hemp is a versatile 
agricultural crop, with multiple applications outside of THC-free 
CBD hemp oil, the evidence base is still limited for the 
conditions presented at dispensaries. Claims that THC-free CBD 
oils, for example, are more effective and with a lower likelihood 
of adverse events that THC/CBD combination oils are still an 
open question. Claims, therefore, to legislators, as part of a 
licensing application, that the proposed dispensary will focus on 
hemp-based CBD products should be treated with caution.  
 
FLOW OF INFORMATION 
At the outset, it should be clear that it is unlikely that the 
registry design would include, or need to include, inputs from 
health care practitioners. Apart from issues of coordinating 
health care provider response and the timing of that response 
over the course of treatment, both of which would impose a 
significant burden on providers, patient self-reporting on 
validated instruments would be a viable and even preferred 
option. In the case of chronic non-cancer pain, there are a range 
of validated PRO instruments that capture both the type of pain 
experience, distinguishing neuropathic from nociceptive pain, 
as well as evaluating the intensity of pain and functional status 
by body location. As shown both by existing evidence from RCTS 
and observational studies together with the detailed responses 
from the Minnesota study, response to botanical cannabis 
formulations can vary by type and location of pain. A dispensary 
should, therefore, be in a position to support claims that are 
specific to pain type and body location. The same argument 
applies to associated symptoms, in particular the experience of 
fatigue, anxiety, depression and sleep experience. Validated 
instruments are available for each of these conditions. Together 
with PROs for pain type and location, these instruments would 
provide a coherent and well-structured framework for tracking 
change over time and calibrating response to therapy by 
cannabis dosing and administrative form. 
 
If claims are to be evaluated against cannabis dosing and 
administrative form, it is important that the registry tracks the 
THC:CBD ratios for products supplied at each dispensary visit. 
Although in their early stages, guidelines for the medicinal 
application of botanical cannabis emphasize, particularly for 
naïve consumers, the importance of starting at a low dose with 
minimum THC and titrating to an effective low THC/high CBD 
product 7. The evidence for this is, however, limited. One 
concern from the Minnesota study, as noted above, is the 
proportion of patients on high THC products. Introducing the 
patient, particularly a naïve consumer, to a high THC dosing 
regimen may not only create risks for severe adverse events 
and cannabis dependence but obscure the clinical value of a 
more calculated and benign dosing regimen. Achieving target 
outcomes (e.g., a 30% reduction in pain intensity within 3 
months) with minimum psychoactive effects should be an 
integral part of the duty of care. It should be the responsibility 
of the dispensary to develop and adhere to dosing and 
formulation guidelines defined by administration route, 
reviewing patient response at regular dispensary visits. The 
question then becomes the willingness of the dispensary to 
host the registry (or contract hosting and administration to a 
third party) and utilize its own staff to coordinate with patients 
with data entry at each dispensary visit.  
 
QUESTIONS LEGISLATORS SHOULD ASK 
Given the feasibility of creating dispensary registries, the next 
question is to set the stage for registry data inputs and data 
outputs by establishing a minimum set of reporting criteria. If, 
for example, a proposed data collection protocol is proposed 
(as might be the case for future Minnesota studies of the 
contribution of botanical cannabis), what questions should a 
legislator ask to establish the status of the proposed registry? 
Or, these might be issues raised when adjudicating applications 
(typically well oversubscribed) for a limited set of state 
dispensary licenses. If there is competition between investors 
or multistate companies for limited state licenses, then it is 
presumably incumbent on legislators and agencies to set 
minimum standards for operational performance and quality in 
health care delivery. After all, in many states there is a 
continuing groundswell of opinion against legalizing access to 
medical marijuana. If this is to be countered, then legislators 
and registry operators need to demonstrate that they recognize 
a duty of care and are committed to achieving credible 
outcomes. 
 
The following questions are proposed as the basis for medical 
marijuana dispensary licensing in the case of chronic non-
cancer pain. Similar questions could be raised in respect of the 
range of other approved treatment conditions: 
 
• Has the dispensary adopted a registry design that 
allows patients with specific pain conditions to be 
monitored over the course of treatment?  
• Does the dispensary have adequate product liability 
insurance to cover adverse outcomes and dispensary 
malpractice? 
• Has this registry design and its data collection and 
reporting protocols been validated in other 
dispensaries? 
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• Does the registry design require inputs from health 
care providers, patients and dispensary staff or only 
the patient and dispensary staff? 
• Is the registry hosted and managed by the dispensary 
or is hosting and management contracted to a third 
party? 
• Does the registry capture data from the patient at the 
initial dispensary visit and for all subsequent visits? 
• Does the registry identify all disease and conditions for 
which medical marijuana has been approved in the 
state reported by the patient? 
• Is the dispensary a separate entity from physician 
groups that advise patients on their eligibility for a 
medical marijuana card and assist in the approval 
process? 
• Does the data capture from patients include 
conditions or disease states that are not approved for 
medical marijuana? 
• Does the registry staff have training that allows a 
clinical evaluation at initial assessment or point of sale 
of botanical marijuana options given comorbid disease 
states and possible drug-drug interactions? 
• Does the registry have access to qualified medical 
professional staff that allows at initial assessment or 
point of sale a clinical evaluation of botanical 
marijuana options given comorbid disease states and 
possible drug-drug interactions? 
• Does the registry have guidelines for the dosing and 
administration of botanical cannabis which meet 
standards proposed for initial dosing, dose titration 
and the avoidance of psychoactive response? 
• Does the registry report the dosing and administrative 
form of botanical cannabis at each dispensary visit?  
• Are the registry clinical staffs equipped to assess 
response to therapy by pain type and location and 
advice on adjustments to the dosing and 
administration regimen? 
• Does the registry capture at each dispensary visit 
prescription medication use including opioid 
formulation? 
• Does the registry capture both clinical responses to 
therapy as well as the patient’s perception of the 
response over baseline?  
• Does the registry utilize validated instruments to 
measure response to therapy? 
• Do the validated instruments capture both responses 
in terms of pain as well as functional status? 
• Do the validated instruments capture response for 
fatigue, anxiety, depression and sleep experience? 
• Is it possible to determine from the instruments 
minimum clinical improvement? 
• Are summary reports provided to the patient and, with 
permission, the provider following each dispensary 
visit?  
• Do the patient summary reports detail clinical 
improvement over base for pain intensity, functional 
status and associated conditions? 
• Does the registry generate dispensary level reports for 
outcomes by target patient group? 
 
INVESTORS AND DISPENSARY RISK 
Without wishing to be unduly alarmist, the lack of a firm 
evidence base to support botanical cannabis dispensing 
recommendations should give pause. Consider the case of CBD. 
The 'conventional' wisdom, as noted above, is that the 
psychoactive THC should be avoided in favor of CBD. Indeed, 
there are companies producing hemp derived CBD oil as the 
preferred product. In the absence of evidence for the relative 
benefits and harms of various THC/CBD ratio combinations 
across the myriad conditions proposed or allowed for botanical 
cannabis, no such judgement should be made. We should be 
looking towards condition specific guidelines, taking account of 
the possibility of patients presenting with multiple allowed 
conditions or symptoms together with other comorbidities. In 
the case of glaucoma, for example, a recent mouse study claims 
that the dominant CBD effect may worsen glaucoma and 
increase eye pressure 8 . While it  has been shown that THC is 
effective in lowering eye pressure, the study found that a 
THC/CBD combination effectively blocked the THC effect. In the 
absence of a firm evidence base, it is incumbent upon 
dispensaries, if they accept a duty of care, to monitor patients 
response to botanical cannabis in both THC/CBD combinations 
or these used separately (and other cannabinoids) to evaluate 
effectiveness.  
 
In the absence of an audit trail which links condition presented 
to the consequent THC/CBD dosing regimens, dispensaries put 
themselves at risk. A situation that is confounded even more 
when registries fail to record condition or indeed fail to have 
condition specific guidelines in place to support staff in making 
recommendations and informing patients as to potential 
harms. The view appears to be that botanical marijuana is a 
‘benign’ product with minimal downside risks. The fact is that 
cannabis is being supplied, to clients who are typically 
described as ‘patients’, in a retail environment where the focus 
is on sales. The only medical marijuana audit that occurs is to 
ensure they do not exceed legislated maximum consumption in 
a given period.   
 
Certainly, companies offer legal marijuana dispensary 
insurance cover, to include product liability and, presumably, 
what may be described as ‘dispensary malpractice’. The 
question is whether a claim will be met by the insurer? The risk 
is that without the ability to demonstrate that the dispensary is 
attempting to minimize product risk through monitoring 
patients, the dispensary may be denied a claim on the grounds 
that it was not demonstrating a reasonable ‘duty of care’. Are 
dispensary counter staff, or even a physician 24/7 phone/text 
backup in a position to advise and monitor patients who seek 
relief from intraocular eye pressure? While glaucoma patients 
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my represent only a fraction of patients, the same arguments 
apply to chronic pain and the other conditions presented at 
dispensaries.. 
 
CONCLUSIONS 
It was argued in the previous commentary that given the 
importance of feedback on the benefits and risks of botanical 
marijuana, state agencies may mandate data collection and 
reporting by the dispensary as a licensing condition if 
dispensary owners are reluctant to make such a commitment. 
In the absence of a registry it is difficult to see how dispensary 
owners could make believable claims for the clinical benefits of 
their dispensary services. Rather, they would fall back on their 
retail presentation in promoting cannabis strains and delivery 
options supported by targeted discounting, putting claims for 
clinical efficacy to one side. 
 
Unless medical marijuana dispensaries, or at least a significant 
proportion of them, invest in a registry model to monitor and 
report patient outcomes with botanical cannabis, there will be 
a reluctance to accept cannabis as a contribution to the 
management of severe or chronic pain. Unfortunately, it is 
unclear at this point as to the willingness of dispensaries to 
commit resources to registry development. Whether this is a 
viable situation is a moot point. Certainly, with evidence from 
Colorado, the introduction of recreational marijuana has had a 
substantial impact on medical marijuana registration. It is not 
clear if this means that patients are now self-medicating or that 
a proportion of medical marijuana certificates were simply a 
cover for recreational marijuana. It may simply reflect pricing 
differentials and an unwillingness to shoulder administrative 
costs and processes for certification. Unfortunately, we will 
never know unless there are efforts to track patients who may 
be presenting with, for example, ‘intractable’ pain conditions. 
We will continue to operate in an information vacuum but with 
some, albeit limited, confidence in the ‘effectiveness’ of 
botanical cannabis.  
 
The impact of a recreational marijuana option should not be 
understated. While it may increase the overall market for 
cannabis, with Colorado for example now having over 500 
medical and recreational shop fronts, it may inhibit the 
medicinal use of cannabis by providers and patients due to the 
continued absence of robust outcomes data. Pursuit of the 
taxation benefits from botanical cannabis should not hide the 
fact that the ultimate goal is to improve patient health. 
 
If we are to encourage dispensaries to support outcomes 
reporting and assessment, then the cost of implementation of 
a registry package should be reasonable. It is not the intention 
to replicate multimillion dollar RCTs or similar studies. The 
intention should be to support a pricing structure for registry 
introduction and long-term hosting, probably by a third party, 
that encourages dispensary and, through the dispensary, 
patient involvement. This may, as noted in the previous 
commentary result in a two-tier medical marijuana dispensary 
structure with participating dispensaries offering provider 
coordinated care management. Reducing barriers to the 
acceptance of the place of medical marijuana in care 
management, particularly for older patients presenting with 
comorbid conditions, would be a major objective. This may 
overcome the reluctance of many states to accept medical 
marijuana programs. 
 
Even with states that have medical marijuana programs, the 
adoption of a registry option for dispensaries would indicate 
their acceptance of the need to support an enhanced evidence 
base for medical marijuana and an effective risk management 
strategy.  Potential benefits in the duty of care and potentially 
improved outcomes for patients should be stressed. Beyond 
the enhancement of the presently fragmented evidence base, 
in the longer term a major benefit would be the utilization of 
observational monitoring of outcomes as inputs to the 
development and adoption of evidence-based, condition-
specific botanical cannabis guidelines. If so, then we may move 
towards a more effective and safer utilization of botanical 
cannabis as an integral part of pathways of care.  
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